Shift Bioscience builds a cell simulation platform that combines generative AI with a high-accuracy, high-throughput biological aging clock to predict which gene sets are most likely to safely rejuvenate specific cell types. The company uses the platform to test, improve, and validate predictions and to identify novel target genes for therapies addressing age-related illnesses. Preliminary results from the platform were presented at the 2024 Gordon Research Conference on Systems Aging. Shift intends to use the newly raised capital to accelerate platform development, advance target discovery, and develop an IP portfolio around identified rejuvenation genes. Management positions this work as a step toward designing regenerative medicines and moving cell rejuvenation therapeutics closer to clinical trials. The company is based in Cambridge, England and is positioning its technology to address multiple diseases of aging.

Total raised

$17M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2024